key: cord-1041633-owm7g2ag
authors: Laing, E.; Epsi, N. J.; Richard, S. A.; Samuels, E. C.; Wang, W.; Vassell, R.; Ewing, D. F.; Herrup, R.; Sterling, S. L.; Lindholm, D. A.; Millar, E. V.; Maves, R. C.; Larson, D. T.; Colombo, R. E.; Chi, S.; Madar, C. S.; Lalani, T.; Ganesan, A.; Fries, A.; Colombo, C. J.; Mende, K.; Simons, M. P.; Schully, K. L.; Weiss, C. D.; Tribble, D. R.; Agan, B. K.; Pollett, S. D.; Broder, C. C.; Burgess, T. H.
title: SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity
date: 2021-05-02
journal: nan
DOI: 10.1101/2021.04.27.21256207
sha: ff6404aca8855aaa84bf3475561420d668a1e1b7
doc_id: 1041633
cord_uid: owm7g2ag

Importance: The persistence of SARS-CoV-2 antibodies may be a predictive correlate of protection for both natural infections and vaccinations. Identifying predictors of robust antibody responses is important to evaluate the risk of re-infection / vaccine failure and may be translatable to vaccine effectiveness. Objective: To 1) determine the durability of anti-SARS-CoV-2 IgG and neutralizing antibodies in subjects who experienced mild and moderate to severe COVID-19, and 2) to evaluate the correlation of age and IgG responses to both endemic human seasonal coronaviruses (HCoVs) and SARS-CoV-2 according to infection outcome. Design: Longitudinal serum samples were collected from PCR-confirmed SARS-CoV-2 positive participants (U.S. active duty service members, dependents and military retirees, including a range of ages and demographics) who sought medical treatment at seven U.S. military hospitals from March 2020 to March 2021 and enrolled in a prospective observational cohort study. Results: We observed SARS-CoV-2 seropositivity in 100% of inpatients followed for six months (58/58) to one year (8/8), while we observed seroreversion in 5% (9/192) of outpatients six to ten months after symptom onset, and 18% (2/11) of outpatients followed for one year. Both outpatient and inpatient anti-SARS-CoV-2 binding-IgG responses had a half-life (T1/2) of >1000 days post-symptom onset. The magnitude of neutralizing antibodies (geometric mean titer, inpatients: 378 [246-580, 95% CI] versus outpatients: 83 [59-116, 95% CI]) and durability (inpatients: 65 [43-98, 95% CI] versus outpatients: 33 [26-40, 95% CI]) were associated with COVID-19 severity. Older age was a positive correlate with both higher IgG binding and neutralizing antibody levels when controlling for COVID-19 hospitalization status. We found no significant relationships between HCoV antibody responses and COVID-19 clinical outcomes, or the development of SARS-CoV-2 neutralizing antibodies. Conclusions and Relevance: This study demonstrates that humoral responses to SARS-CoV-2 infection are robust on longer time-scales, including those arising from milder infections.

The immune correlates of protection against severe acute respiratory syndrome 

The magnitude of the antibody response to SARS-CoV-2 infection has been positively 85 correlated with COVID-19 severity [18] [19] [20] [21] [22] [23] [24] [25] , but the confounding effect of age on this association 86 remains unresolved [26] [27] [28] . Even less understood is whether cross-reactive seasonal human This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 2, 2021. ; https://doi.org/10.1101/2021.04.27.21256207 doi: medRxiv preprint 5 2 infection. From these participants, we analyzed spike protein IgG binding in a serial collection 123 of 764 serum samples from 250 (outpatients n= 192, inpatients n= 58) participants who were 124 followed through six and twelve months-post-enrollment. Six months serum samples from these 125 participants were collected at a median 188 days post-symptom onset (dpso), IQR= 15. Of 126 these 250 participants, 19 (outpatients, n= 11; inpatients= 8) had available sera drawn twelve 127 months from the onset of symptoms and prior to vaccination, allowing long-term monitoring of This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 2, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 analyses were used to explore antibody half-life (T 1/2 ) trends utilizing subjects with ≥ 2 174 longitudinal sera samples, and, based on best-fit, either a one-phase or two-phase decay model 175 was preferred. When single models for all the datasets were not preferred or a best-fit single 176 curve was ambiguous, a robust fit without curve fitting was applied and the mean of all subjects' 177 individual T 1/2 was calculated; in several instances T 1/2 exceeded 1000 days and were reported 178 as >1000. We used Brown-Forsythe and Welch's ANOVA to compare age-stratified log10- This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

We observed 95% (183/192) of outpatients and 100% of inpatients (58/58) remained 201 seropositive at six months-post, and 9/11 outpatients and 8/8 inpatients remained seropositive 202 at 12 months-post symptom onset. A one-phase decay of the IgG response of inpatients 203 calculated a T 1/2 >1000 days ( Figure 1A ). IgG responses displayed greater heterogeneity 204 among outpatients than inpatients and a one-phase decay curve modeled a T1/2= 1232 days 205 ( Figure 1A ). Next, we sought to investigate whether the magnitude or duration of the IgG 

twelve months-post we found no differences in geometric mean IgG binding between inpatients 216 (14, 755 [95% CI: 11, 472] ) and outpatients (10, 588 [95% CI: 6, 460 This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 2, 2021. ; https://doi.org/10.1101/2021.04.27.21256207 doi: medRxiv preprint 9 inpatient T1/2 neutralizing antibody responses of 88 days and a two-phase decay of outpatient 226 neutralizing antibody responses calculated a mean fast/slow-T1/2 of 77/132 days ( Figure 1C ).

The neutralizing antibody GMT was greater for inpatients than outpatients during both early 

Age correlation with antibody durability may be explained by age-specific clinical severity 245 Because age is associated with hospitalization status, we used a multivariate regression 246 model to explore antibody magnitude and durability on the basis of COVID-19 severity and age 247 (groups: 18-44, >44-64, and ≥ 65-years-old). This analysis revealed that during early 248 convalescence IgG levels were higher for all inpatient participants, and increased with age for 249 outpatients with significantly higher IgG-binding levels in This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 2, 2021. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Notably, when we controlled for hospitalization status, older age was positively 305 correlated with robust positive antibodies and neutralizing antibody responses. This suggests a 306 lack of immunosenescence driving waning humoral responses or seroreversion as all instances 307 of seroreversion between six to twelve months-post symptom onset occurred in outpatient 308 participants <65 years old (median age 30, Q1=26, Q3=43). Although, the association between 309 age and disease severity may confound this observation. The interaction between age, severity 310 and adaptive responses is complex 48,49 ; we noted that age ≥ 65 years was significantly 311 associated with the magnitude and durability of IgG responses for outpatients, whereas no 312 differences were found for inpatients across the age groups. However, sample size was smaller 313 in the inpatient group so this observation needs to be investigated further. Additionally, the 314 magnitude of the early neutralizing antibody response increased incrementally in outpatients 315 and inpatients age groups >44 years old. Interestingly, no significant differences in neutralizing 316 antibody levels were observed across age groups by six months after symptom onset.

When we assessed HCoV seroresponses in our cohort, we found no association with This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Additionally, we thank Shreshta Phogat (USU, HJF) for technical assistance. We also thank the This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 2, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 2, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

MFI, median fluorescence intensity; dpso is from zero to twelve months; boxplots denote 649 median, first quartile (25 th percentile) and third quartile (75 th percentile); statistical significance This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 2, 2021. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 2, 2021. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 2, 2021. ; https://doi.org/10.1101/2021.04.27.21256207 doi: medRxiv preprint

Durability of Responses after SARS-CoV-2 427 mRNA-1273 Vaccination

Evidence for antibody as a protective 429 correlate for COVID-19 vaccines. medRxiv

Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable 432

Robust neutralizing antibodies to SARS-CoV-2 434 infection persist for months

Antibody Responses 8 Months after Asymptomatic 436 or Mild SARS-CoV-2 Infection. Emerging Infectious Disease journal

Neutralizing antibody titres in SARS-CoV-2 438 infections

Immunological memory to SARS-CoV-2 assessed for 440 up to 8 months after infection

SARS-CoV-2-directed antibodies persist for 442 more than six months in a cohort with mild to moderate COVID-19

Longitudinal assessment of anti-SARS-CoV-2 immune 444 responses for six months based on the clinical severity of COVID-19

Sustainability of SARS-CoV-2 Induced Humoral 446

Immune Responses in COVID-19 Patients from Hospitalization to Convalescence Over 447 Six Months

A Case of Early Reinfection With Severe 449

Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Reinfection of 452 COVID-19 after 3 months with a distinct and more aggressive clinical presentation: Case 453 report

Evidence of Severe Acute Respiratory Syndrome 455

Coronavirus 2 Reinfection After Recovery from Mild Coronavirus Disease

Recurrence of SARS-CoV-2 458 infection with a more severe case after mild COVID-19, reversion of RT-qPCR for 459 positive and late antibody response: Case report

Re-infection with SARS-CoV-2: What Goes Around May Come 461 Back Around

Neutralizing Antibodies Correlate with 463 Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High 464

Attack Rate

Antibody Status and Incidence of SARS-466

CoV-2 Infection in Health Care Workers

Disease Severity, Fever, Age, and Sex

Correlate With SARS-CoV-2 Neutralizing Antibody Responses